Real-World Treatment Outcomes in Patients with Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis Who Transitioned from Efgartigimod to Ravulizumab (P4-8.003)
To describe real-world treatment outcomes in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (AChR+ gMG) who transitioned from efgartigimod to ravulizumab.
Authors
- Raghav Govindarajan (ORCID: https://orcid.org/0000-0003-0419-9072)
Institutions
- St. Elizabeths Hospital (US)
- St. Elizabeth's Hospital (PK)
- Humboldt District Hospital (CA)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211903
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39